{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:18:35Z","timestamp":1792725515029,"version":"4.5.0"},"reference-count":166,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T00:00:00Z","timestamp":1593043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:p>Biliary tract infections (BTIs), including cholangitis and cholecystitis, are common causes of bacteremia. Bacteremic BTIs are associated with a mortality rate of 9\u201312%. The extent to which antibiotics are excreted in the bile and the ratio of their exposure to the minimum inhibitory concentration of the infecting organism are among the important factors for the treatment of BTIs. This review updates health care professionals on the distribution of antibiotics in the common bile duct, gallbladder, and gallbladder wall. Antibiotic efficacy in treating BTIs based on the latest available clinical studies is also discussed. The efficacy and pharmacokinetics of 50 antibiotics are discussed. Overall, most antibiotic classes exhibit biliary penetration that translates into clinical efficacy. Only seven antibiotics (amoxicillin, cefadroxil, cefoxitin, ertapenem, gentamicin, amikacin, and trimethoprim\/sulfamethoxazole) had poor biliary penetration profiles. Three antibiotics (ceftibuten, ceftolozane\/tazobactam, and doripenem) had positive clinical outcomes despite the lack of pharmacokinetic studies on their penetration into the biliary tract. Conflicting efficacy data were reported for ampicillin despite adequate biliary penetration, whereas conflicting pharmacokinetic data were reported with cefaclor and moxifloxacin. Even in the absence of supportive clinical studies, antibiotics with good biliary penetration profiles may have a place in the treatment of BTIs.<\/jats:p>","DOI":"10.1002\/phar.2431","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T15:10:07Z","timestamp":1591110607000},"page":"672-691","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Antibiotics in the Biliary Tract: A Review of the Pharmacokinetics and Clinical Outcomes of Antibiotics Penetrating the Bile and Gallbladder Wall"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0369-9094","authenticated-orcid":false,"given":"Abrar K.","family":"Thabit","sequence":"first","affiliation":[{"name":"Pharmacy Practice Department Faculty of Pharmacy King Abdulaziz University Jeddah Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,6,25]]},"reference":[{"key":"e_1_2_5_2_1","volume-title":"Harrison\u2019s principles of internal medicine","author":"Greenberger NJ","year":"2018"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00534-002-0710-1"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1980.tb00622.x"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1086\/649554"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2016.261"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks062"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.4291\/wjgp.v9.i1.1"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2007.064683"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000069712"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00534-006-1160-y"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00534-006-1157-6"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-013-9541-z"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-014-9636-1"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199957010-00007"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp060011k"},{"key":"e_1_2_5_17_1","volume-title":"Performance standards for antimicrobial susceptibility testing: thirtieth informational supplement [document M100\u2013S30]","author":"Clinical and Laboratory Standards Institute","year":"2020"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000237832"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/8.Supplement_5.S589"},{"key":"e_1_2_5_20_1","first-page":"69","article-title":"Amoxycillin levels in human serum, bile, gallbladder, lung, and liver tissue","volume":"19","author":"Kiss IJ","year":"1981","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01964.x"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.6.4.426"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01655872"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800680421"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1021638"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000238075"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01659752"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01299860"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/4.Supplement_2.S346"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e3282f1c985"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199206000-00008"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2005.11.007"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.11.1718"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01650757"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/29.6.711"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.Supplement_2.S181"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/SMJ.0b013e318205de10"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.11.2658"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.3.787"},{"key":"e_1_2_5_40_1","first-page":"253","article-title":"A study on the concentrations of levofloxacin in the gallbladder tissue and bile of patients [in Japanese]","volume":"3","author":"Hukagawa H","year":"1992","journal-title":"Jpn J Antibiot"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dgk056"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198700341-00010"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.2.352"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00554664"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.8.6.713"},{"key":"e_1_2_5_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl403"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.11.4427-4429.2004"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01774-10"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn442"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-84-2-168"},{"key":"e_1_2_5_51_1","doi-asserted-by":"publisher","DOI":"10.1159\/000221434"},{"key":"e_1_2_5_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02393539"},{"key":"e_1_2_5_53_1","doi-asserted-by":"publisher","DOI":"10.1159\/000221794"},{"key":"e_1_2_5_54_1","doi-asserted-by":"publisher","DOI":"10.1159\/000238489"},{"key":"e_1_2_5_55_1","first-page":"105","article-title":"Pharmacokinetic study of rifampicin in biliary surgery","volume":"16","author":"Kiss IJ","year":"1978","journal-title":"Int J Clin Pharmacol Biopharm"},{"key":"e_1_2_5_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1954.tb01677.x"},{"key":"e_1_2_5_57_1","unstructured":"US Food and Drug Administration.Antibacterial susceptibility test interpretive criteria January 2 2020. Available fromhttps:\/\/www.fda.gov\/STIC. Accessed February 19 2020."},{"key":"e_1_2_5_58_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.8.1636"},{"key":"e_1_2_5_59_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.22.3.488"},{"key":"e_1_2_5_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/31.suppl_A.39"},{"key":"e_1_2_5_61_1","first-page":"135","article-title":"Biliary elimination of ticarcillin plus clavulanic acid (Claventin): experimental and clinical study","volume":"27","author":"Brogard JM","year":"1989","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"e_1_2_5_62_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.3.5824.441"},{"key":"e_1_2_5_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/10.suppl_B.33"},{"key":"e_1_2_5_64_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/11.suppl_A.217"},{"key":"e_1_2_5_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01874087"},{"key":"e_1_2_5_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/12.suppl_A.255"},{"key":"e_1_2_5_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00981132"},{"key":"e_1_2_5_68_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.10.1588"},{"key":"e_1_2_5_69_1","first-page":"287","article-title":"Concentration of cefixime in bile, gallbladder wall and serum after preoperative administration in patients undergoing cholecystectomy","volume":"12","author":"Moorthi K","year":"1990","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"e_1_2_5_70_1","first-page":"329","article-title":"Evaluation of cefixime biliary disposition in the isolated perfused rabbit liver model and in humans","volume":"18","author":"Westphal JF","year":"1992","journal-title":"Drugs Exp Clin Res"},{"key":"e_1_2_5_71_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.18.6.980"},{"key":"e_1_2_5_72_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.29.6.1101"},{"key":"e_1_2_5_73_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.17.7.495"},{"key":"e_1_2_5_74_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/127.3.299"},{"key":"e_1_2_5_75_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.4.5.538"},{"key":"e_1_2_5_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800620406"},{"key":"e_1_2_5_77_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/124.Supplement_1.S106"},{"key":"e_1_2_5_78_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.2.327"},{"key":"e_1_2_5_79_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.2.352"},{"key":"e_1_2_5_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1984.tb02781.x"},{"key":"e_1_2_5_81_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.20.4.515"},{"key":"e_1_2_5_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02567.x"},{"key":"e_1_2_5_83_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp318"},{"key":"e_1_2_5_84_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P100"},{"key":"e_1_2_5_85_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365527709181365"},{"key":"e_1_2_5_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1965.tb02094.x"},{"key":"e_1_2_5_87_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.3.5662.88"},{"key":"e_1_2_5_88_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/2.2.195"},{"key":"e_1_2_5_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00558335"},{"key":"e_1_2_5_90_1","first-page":"412","article-title":"Ampicillin versus cefamandole in biliary tract surgery. A prospective, randomized clinical and bacteriological study","volume":"50","author":"Levi JU","year":"1984","journal-title":"Am Surg"},{"key":"e_1_2_5_91_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1989.00390060033007"},{"key":"e_1_2_5_92_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.8.1231"},{"key":"e_1_2_5_93_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/26.suppl_B.167"},{"key":"e_1_2_5_94_1","first-page":"23","article-title":"A randomized study of cefepime versus the combination of gentamicin and mezlocillin as an adjunct to surgical treatment in patients with acute cholecystitis","volume":"177","author":"Yellin AE","year":"1993","journal-title":"Surgery Gynecol Obstet"},{"key":"e_1_2_5_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1091-255X(00)80109-2"},{"key":"e_1_2_5_96_1","first-page":"700","article-title":"A note on the concentration of nafcillin in human bile","volume":"40","author":"Green GR","year":"1965","journal-title":"Mayo Clin Proc"},{"key":"e_1_2_5_97_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.2.309"},{"key":"e_1_2_5_98_1","first-page":"462","article-title":"Biliary pharmacokinetic profile of piperacillin: experimental data and evaluation in man","volume":"11","author":"Brogard JM","year":"1990","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"e_1_2_5_99_1","doi-asserted-by":"publisher","DOI":"10.1177\/030006058301100106"},{"key":"e_1_2_5_100_1","first-page":"275","article-title":"Broad spectrum penicillin as an adequate therapy for acute cholangitis","volume":"171","author":"Thompson JE","year":"1990","journal-title":"Surgery Gynecol Obst"},{"key":"e_1_2_5_101_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v10.i15.2281"},{"key":"e_1_2_5_102_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/17.suppl_C.65"},{"key":"e_1_2_5_103_1","first-page":"759","article-title":"Clinical studies of BRL 28500 (clavulanic acid\/ticarcillin) in the treatment of intraperitoneal infections and biliary tract infections","volume":"40","author":"Sakai K","year":"1987","journal-title":"Jpn J Antibiot"},{"key":"e_1_2_5_104_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/131.6.625"},{"key":"e_1_2_5_105_1","first-page":"540","article-title":"Biliary excretion and concentration of cefazolin","volume":"66","author":"Ram MD","year":"1976","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_5_106_1","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1987.01400200068012"},{"key":"e_1_2_5_107_1","first-page":"15","article-title":"Antibiotic prophylaxis in high\u2010risk biliary operations: multicenter trial of single preoperative ceftriaxone versus multidose cefazolin","volume":"148","author":"Kellum JM","year":"1984","journal-title":"Am J Surg"},{"key":"e_1_2_5_108_1","first-page":"44","article-title":"A single preoperative dose of cefazolin prevents postoperative sepsis in high\u2010risk biliary surgery","volume":"27","author":"Lewis RT","year":"1984","journal-title":"Can J Surg"},{"key":"e_1_2_5_109_1","doi-asserted-by":"publisher","DOI":"10.1159\/000237950"},{"key":"e_1_2_5_110_1","first-page":"272","article-title":"Excretion of cefuroxime in biliary disease","volume":"158","author":"Thomas M","year":"1984","journal-title":"Surgery Gynecol Obstet"},{"key":"e_1_2_5_111_1","first-page":"193","article-title":"Peroperative cefuroxime v. long\u2010term ampicillin and metronidazole in high\u2010risk biliary and gastric surgery. A multicentre trial","volume":"153","author":"Jensen LS","year":"1987","journal-title":"Acta Chir Scand"},{"key":"e_1_2_5_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/0195-6701(88)90008-4"},{"key":"e_1_2_5_113_1","first-page":"841","article-title":"Antibiotic prophylaxis for ERCP: a randomized clinical trial comparing ciprofloxacin and cefuroxime in 200 patients at high risk of cholangitis","volume":"7","author":"Mehal WZ","year":"1995","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"e_1_2_5_114_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800800742"},{"key":"e_1_2_5_115_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.30.1.104"},{"key":"e_1_2_5_116_1","first-page":"237","article-title":"Cefotetan versus cefoxitin in the treatment of patients with biliary sepsis assessed by a biliary sepsis score","volume":"7","author":"Basoli A","year":"1988","journal-title":"Chemioterapia"},{"key":"e_1_2_5_117_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.22.4.709"},{"key":"e_1_2_5_118_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00607958"},{"key":"e_1_2_5_119_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/10.3.207"},{"key":"e_1_2_5_120_1","first-page":"555","article-title":"Treatment of acute biliary tract infections with ofloxacin: a randomized, controlled clinical trial","volume":"34","author":"Karachalios GN","year":"1996","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_5_121_1","doi-asserted-by":"publisher","DOI":"10.1159\/000238644"},{"key":"e_1_2_5_122_1","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2010.005"},{"key":"e_1_2_5_123_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/8.suppl_B.293-b"},{"key":"e_1_2_5_124_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.24.1.104"},{"key":"e_1_2_5_125_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/19.5.671"},{"key":"e_1_2_5_126_1","volume-title":"Product Information: FORTAZ\u00ae, ceftazidime for\u00a0intravenous injection","year":"2017"},{"key":"e_1_2_5_127_1","volume-title":"Product Information: AVYCAZ\u00ae, ceftazidime and avibactam for\u00a0intravenous injection","year":"2019"},{"key":"e_1_2_5_128_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/12.1.27"},{"key":"e_1_2_5_129_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198100221-00021"},{"key":"e_1_2_5_130_1","first-page":"30","article-title":"Cefepime for infections of the biliary tract","author":"Thompson JE","year":"1993","journal-title":"Surg Gynecol Obstet"},{"key":"e_1_2_5_131_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S180905"},{"key":"e_1_2_5_132_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.993381"},{"key":"e_1_2_5_133_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.9.2057"},{"key":"e_1_2_5_134_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-009-0067-1"},{"key":"e_1_2_5_135_1","volume-title":"Product Information: RECARBRIO\u00ae, imipenem, cilastatin, and relebactam intravenous injection","year":"2019"},{"key":"e_1_2_5_136_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00497-11"},{"key":"e_1_2_5_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.01.023"},{"key":"e_1_2_5_138_1","volume-title":"Product Information: VABOMERE\u00ae, meropenem and vaborbactam for intravenous injection","year":"2019"},{"key":"e_1_2_5_139_1","volume-title":"Product Information: MERREM\u00ae, meropenem for intravenous injection","year":"2019"},{"key":"e_1_2_5_140_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP201786"},{"key":"e_1_2_5_141_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2011.00783.x"},{"key":"e_1_2_5_142_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-014-0960-0"},{"key":"e_1_2_5_143_1","volume-title":"Product Information: INVANZ\u00ae, ertapenem for intravenous or intramuscular injection","year":"2020"},{"key":"e_1_2_5_144_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.25.3.358"},{"key":"e_1_2_5_145_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/13.Supplement_7.S616"},{"key":"e_1_2_5_146_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00542200"},{"key":"e_1_2_5_147_1","first-page":"1417","article-title":"Transfer of ciprofloxacin to bile and determination of biliary metabolites in humans","volume":"36","author":"Tanimura H","year":"1986","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_5_148_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01641434"},{"key":"e_1_2_5_149_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/35.6.855"},{"key":"e_1_2_5_150_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-199815060-00005"},{"key":"e_1_2_5_151_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007997709109341"},{"key":"e_1_2_5_152_1","doi-asserted-by":"publisher","DOI":"10.1086\/431676"},{"key":"e_1_2_5_153_1","volume-title":"Product Information: XERAVA\u00ae, eravacycline for intravenous injection","year":"2018"},{"key":"e_1_2_5_154_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb01007.x"},{"key":"e_1_2_5_155_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt196123308"},{"key":"e_1_2_5_156_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-081X(199810)19:7<433::AID-BDD122>3.0.CO;2-Z"},{"key":"e_1_2_5_157_1","doi-asserted-by":"publisher","DOI":"10.3410\/M4-4"},{"key":"e_1_2_5_158_1","first-page":"25","article-title":"Teicoplanin: Part 2. Evaluation of its use in the biliary system","volume":"15","author":"Antrum RM","year":"1989","journal-title":"Drugs Exp Clin Res"},{"key":"e_1_2_5_159_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01318.x"},{"key":"e_1_2_5_160_1","doi-asserted-by":"publisher","DOI":"10.1086\/499533"},{"key":"e_1_2_5_161_1","first-page":"61","article-title":"Results of the North American trial of piperacillin\/tazobactam compared with clindamycin and gentamicin in the treatment of severe intra\u2010abdominal infections","volume":"573","author":"Investigators of the Piperacillin\/Tazobactam Intra\u2010abdominal Infection Study Group","year":"1994","journal-title":"Eur J Surg Suppl"},{"key":"e_1_2_5_162_1","first-page":"725","article-title":"Disposition and metabolism of rifapentine, a rifamycin antibiotic, in mice, rats, and monkeys","volume":"26","author":"Emary WB","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_5_163_1","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.37.1066"},{"key":"e_1_2_5_164_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-013-0616-7"},{"key":"e_1_2_5_165_1","first-page":"83","article-title":"Chloramphenicol toxicity","volume":"12","author":"Holt D","year":"1993","journal-title":"Adverse Drug React Toxicol Rev"},{"key":"e_1_2_5_166_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00527-17"},{"key":"e_1_2_5_167_1","doi-asserted-by":"publisher","DOI":"10.1211\/jpp.59.7.0007"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.2431","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2431","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2431","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2431","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:13:36Z","timestamp":1761048816000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,25]]},"references-count":166,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1002\/phar.2431"],"URL":"https:\/\/doi.org\/10.1002\/phar.2431","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,25]]},"assertion":[{"value":"2020-06-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}